A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Acarbose; Metformin; Nateglinide; Pioglitazone; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DECIDE
- Sponsors AstraZeneca
- 09 Jan 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 09 Jan 2018 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 10 Jun 2017 Biomarkers information updated